Front. Mol. Neurosci. Frontiers in Molecular Neuroscience Front. Mol. Neurosci. 1662-5099 Frontiers Media S.A. 10.3389/fnmol.2022.979385 Molecular Neuroscience Erratum Erratum: Long March Toward Safe and Effective Analgesia by Enhancing Gene Expression of Kcc2: First Steps Taken Frontiers Production Office * Frontiers Media SA, Lausanne, Switzerland *Correspondence: Frontiers Production Office production.office@frontiersin.org

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

This article was submitted to Pain Mechanisms and Modulators, a section of the journal Frontiers in Molecular Neuroscience

 05 07 2022 2022 15 979385 27 06 2022 27 06 2022 Copyright © 2022 Frontiers Production Office. 2022 Frontiers Production Office

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 An Erratum on Long March Toward Safe and Effective Analgesia by Enhancing Gene Expression of Kcc2: First Steps Taken by Liedtke, W. (2022). Front. Mol. Neurosci. 15:865600. doi: 10.3389/fnmol.2022.865600 pain spinal cord dorsal horn KCC2 Kcc2 gene expression enhancer GSK3 delta-catenin Kaiso

Due to a production error, the “Conflict of Interest” statement incorrectly stated that “WL was a full-time” instead of “WL is a full-time.”

The corrected section should read:

“WL is a full-time executive employee of Regeneron Pharmaceuticals, Tarrytown, NY, United States.”

The publisher apologizes for this mistake. The original version of this article has been updated.